PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PharmaTher Holdings Ltd.’s affiliate, Sairiyo Therapeutics, has been greenlit to start a Phase 1 clinical trial in Australia for PD-001, a reformulated version of the drug cepharanthine, which shows promise in treating cancers and medical emergencies. The success of the trial could lead to advanced clinical trials in the U.S. and further leverage cepharanthine’s historically recognized therapeutic benefits, despite its low oral bioavailability in the past.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.